Piper Sandler Reiterates Overweight Rating on LENZ Therapeutics Inc (LENZ)

August 15, 2024 8:44 AM EDT Send to a Friend
Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $36.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login